Oliver Wyman January 23, 2025
Dealmaking, cost containment, and emerging therapeutic areas took center stage at the 2025 J.P. Morgan Healthcare Conference.
Buckle your seatbelts, 2025 could be a busy year for healthcare dealmaking. That’s one takeaway from our time at the J.P. Morgan Healthcare Conference. During our week in San Francisco, we met with leaders from health systems, pharmaceutical companies, banks, and investment firms. There was a healthy dose of optimism that dealmaking will rebound from a relatively slow 2023 and 2024. In fact, two major deals were unveiled at the conference — Johnson & Johnson’s acquisition of biotechnology company Intra-Cellular Therapies for $14.6 billion and GSK’s purchase of IDRx, which develops precision cancer medicines, for $1 billion.
We identified four overarching trends to...
Today's Sponsors
Today's Sponsor